Stifel has recently initiated Cullinan Therapeutics Inc (CGEM) stock to Buy rating, as announced on May 1, 2024, according to Finviz. Earlier, on April 15, 2024, William Blair had initiated the stock ...

Nicholas Cullinan, the new director of the British Museum, has announced a groundbreaking $1.3 billion transformation plan, ...

Wedbush analyst Robert Driscoll initiated coverage with a Buy rating on Cullinan Management (CGEM – Research Report) today and set a ...

The city of Peoria is putting together an effort to buy a trio of prominent buildings in Downtown Peoria for potential ...

BTIG analyst Julian Harrison maintained a Buy rating on Cullinan Management (CGEM – Research Report) yesterday and set a price target of ...

The Human Research Ethics Committee (HREC) in Australia has granted clearance for Cullinan Therapeutics to commence an ...

CAMBRIDGE, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a biopharmaceutical company focused on developing ...

The newly-evolved Rolls-Royce Cullinan Series II appeals to the discerning tastes of ultra-luxury SUV enthusiasts through ...

Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM – Get Free Report) have been assigned a consensus rating of “Buy” from the six ratings firms that are currently covering the stock ...

Sept. 14, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today shared updated data in ...

Rolls-Royce has unveiled the Cullinan Series II, marking a bold evolution of its renowned super-luxury SUV. This latest ...

On Monday, H.C. Wainwright maintained a Buy rating and a $28.00 stock price target for NASDAQ:CGEM, Cullinan Oncology Inc., following the company's presentation of positive data at a recent medical ...